Phase III trial demonstrates a first for Jardiance

Developed and marketed by family-owned German Boehringer Ingelheim and the USA’s Eli Lilly (NYSE: LLY), their drug Jardiance (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically-significant reduction 0in the primary outcome of HbA1c in children.

Presented today at the International Diabetes Federation (IDF) World Diabetes congress 2022, the DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically-significant reduction in HbA1c (a marker of average blood sugar) with Jardiance compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.

When Jardiance was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).